Feds rebuff Pfizer's pleas to speed up supplies of COVID-19 vaccine raw materials: reports Ellume's COVID-19 test nabs first at-home, over-the-counter emergency use authorization 7 predictions for what lies ahead for health tech in 2021 Sanofi promised pandemic hazard pay to vaccine plant workers, then offered 3 days off instead, lawsuit says PwC: Providers with health plans and value-based care deals in good position heading into 2021 BioNTech, through Fosun deal, pledges 100M coronavirus vaccine doses for China RxAdvance's Sculley: What the PBM of the future might look like Nference matches B round with a new $60M financing, eyes coronavirus work Biopharma roundup: Lilly antibodies underused in U.S.: Slaoui Featured Story | By Arlene Weintraub Pfizer could provide the U.S. more than the initial 100 million COVID-19 vaccine doses it promised, but it needs government help to get its hands on enough raw materials, CEO Albert Bourla said in a TV interview. But so far, the feds are reportedly prioritizing the needs of rival vaccine makers like Moderna. read more |
| |
|---|
|
Top Stories By Ben Adams Ellume has been given an emergency use authorization for its OTC pandemic test you can take at home. read more By Heather Landi Healthcare stakeholders got out their crystal balls and shared their thoughts with Fierce Healthcare on what changes will come for the healthcare technology sector in 2021 and how healthcare organizations will adapt. read more By Eric Sagonowsky As the pandemic heated up this spring, Sanofi scrambled to make sure its plants would continue to turn out the drugs and vaccines patients needed—and it offered certain workers hazard pay as part of that effort. But according to a new lawsuit, the French drugmaker hasn't paid up. read more By Robert King The hospital industry is in for an uneven recovery in 2021 from the COVID-19 pandemic, as systems with health plans and value-based care arrangements are in a better financial position, a new report from PwC found. read more By Fraiser Kansteiner BioNTech, through its arrangement with local drugmaker Shanghai Fosun, will supply China with an initial 100 million doses of its mRNA vaccine, BNT162—should the shot pass muster with domestic regulators. BioNTech plans to source the doses from its production facilities in Germany. read more By Paige Minemyer It's not a secret that the healthcare industry is slow to change. With these increasing calls for evolution, it begs the question: What would the PBM "of the future" look like? read more By Ben Adams It’s been a good end to the year for data analytics firm nference, ending the year as it started: with a $60 million funding round and a deal with the Mayo Clinic. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Lilly and Regeneron's antibodies aren't reaching patients, Warp Speed's Slaoui said. A Sanofi lab tech sued over promised hazard pay. Ellume's home COVID test won an emergency nod. Valeneva launched a phase 1/2 trial of its shot candidate. And British American Tobacco was cleared for human trials of its vaccine. read more |
